CHAMPIONING MEDICALLY INTEGRATED ONCOLOGY:

Celebrating a Decade of Impact



NCODA PQI in Actions: Practical Strategies to Transform Oncology Care

Rebecca Bahr, PharmD, MBA
American Oncology Network

Paulina Barbero, BSN, RN
Northwell Health


Nick Bouchard, PharmD
HOACNY



PQI in Action







What is a Positive Quality Intervention?



Desmoid Tumors (or fibromatoris or aggressive fibromatoris)

Writin By: Teny Philip, MD Northwell Health Positive Quality Intervention: Niragacestat (OGSIVEO*) use in Management of Adults with Progressing

Specificate This POF will discuss the initiation and encountered of adult periods with descript nations (DT) with niregocestia (OGSIVEO*).

Buckground: Nicogacoust (OGSIVEOR) is an enal temption general secretare inhibitor indicated for adult paricans with progressing descend tumors who require systemic treatment." Descend tumors are nare, nonconcerns, locally aggressive tensors. They may accor to any materiacal location, and, while affecting all ages, often scoop in people 20.34 years old. 32 lighthition of gamma secretus prevents savination of the notch receptor and development effects that may contribute to distract turner greech. Nicegacostal is recommended: by the National Comprobensive Cannot Notworkth (NCCNR) on a category 1, preferred systemic through option for patients with despaid tunions (aggressive fibrematoris)."

The efficient and sofety of ninoseconal were demonstrated through envilances in the Deft study. Deft was a phase 3 international, multipoeter, double-blind, madentard (1.1), placebo-cosmolial trial of stogacostar in 142 odalis with pragresping (120%) desented turnors (DT) per BECIST version 1.1 estions within 12 months prior to treatment sixtaction. Potents were randomized to and strapporatel (150 mg) or placebe twice daily, taken continuously in 29-dus cycles until disease progression or unacceptable tousity. Nitogacemat demonstrated a statistically significant improvement in the primary cadpoint, progression-the survival (IWS), with TI% reduction in the risk of disease progression compared to placeby thansed ratio = 0.29 [95% CT | 0.15. 0.55]; P=0.801). The PPS benefit was shown across patients who received grian fluragy with hytosine kinuse. inhibitors or chemotherapy. In addition, mingaconal resulted in a statistically significant improvement in the sevendery embraint of objects ve corporar rate (CRR, 41%, x=24 (45% CL, 29.8, 53.8) vs 3%, x=6, (45% CL, 3.1, 17.3), respectively; P-2.000). At Cycle 10, ninegatorial demonstrated statistically significant and chinoolly recurringful improvement in all prospectful assessments of pution-reported outcomes of pain, DT-specific everytors burden, physical functioning, role functioning (P-0.001), and crossall quality of life (P-0.001). The most common to 15% adverse mactions experienced by patients who received airregacestar were distribus. renatus tenicity, rush, massis. Brigas, morastitic handsafus, abdominal pain cough, dispesia, apper respinsory tract infection, and dyspans. Most (95%) adverse events were Grade 1 or 2 to patterns treated with ninogacental. Laboratory discrepations (31.5%) that worked from handless in patients who received straggeostat in Delliwere decreased phosphate, increased arise glacese, increased urine protein, increased AST, increased ALT, and decreased paramitian. Describ, investigators identified evadors resisting events in 27 of 36 (75%) families of reproductive perential on ninegocostat, based on abnormal reproductive hornests levels and/or prosence of perimonopassal symptoms (e.g., changes in resentinal cycle regularity). However, investigates repented that coursian localisty resolved as 71% (1074) while reserving managenestat and in 190% (11/31) after stopping. thregaerstat for any reason (encluding 2 pariests for whom follow-up data were not available;)

PQI Process: Upon receiving prescription for nitogacestat (OGSIVEO*)1

- Confirm diagnosis of a parient with progressing DT who require systemic treatment.
- Verify dose the recommended design is 150 mg by mouth BID administered orally until disease. programaion or unaccuptable taxicity
 - Available tablet strangths
 - 100 mg (14 count kinter pack)
 - 150 mg (14-count blister pack)
- Dose modifications for adverse reactions.

COPPLET ANY NOTICE SHOULD be in the parties from Charles Country and Control of the collection of the control of the collection of the col alicabet mobal artics, and from our substitute for the order of a qualified buildname electronic. This plottees does not come of secting information when the period to pay distribute, there provides a pay distribute and the conditions. The manifest condition of the provides are payed to pay distribute. and provided in Emply replacations, accommodation, or decoming of this contribution in 1900 the NOORA discount report by improve of the believed on and and account on before relating to be account. We describe taking the profession countries to the first the profession before the profession of a for bothcar province. It is to belieful to the reproducts to each pushes from a publication professional Carlot LEACT

- Positive Quality Intervention (PQI): A precise and concise peer-reviewed clinical guidance resource
- Created by practitioners, for practitioners
- Standardize best practices in oral and IV oncology therapies
- Support consistent, patient-centered care across the team





What are Treatment Support Kits (TSKs)?

 Drug specific kits designed to support patients through their cancer therapy and help with common adverse events

Available TSKs

- Abemaciclib
 - · (Loperamide and Non-Loperamide)
- · Abiraterone Acetate
- Cabozantinib
- Capecitabine
- Fruquintinib
- Inavolisib
- Mirdametinib
- Neratinib
- Nirogacestat
- Pacritinib
- Tivozanib
- Temozolomide









Treatment Discussion Guide


Key Features of the Guide Include:

- Role-Specific Questions & Recommendations
 Practical, thoughtful prompts that encourage open dialogue with patients—customized for each team role.
- Actionable Patient Education Pearls
 Guidance on topics like adherence, drug
 interactions, monitoring, financial support, and
 more.
- Patient-Centered Approach
 Every section is designed to support better understanding, emotional reassurance, and proactive care.



One Team, One Mission

- PQIs align physicians, APPs, pharmacists, nurses, and pharmacy technicians
- Improve communication and streamline workflows
- Support education and timely interventions





Ogsiveo® (Nirogacestat) in Action



- Oral targeted gamma secretase inhibitor indicated for adult patients with progressing desmoid tumors who require systemic treatment
- Desmoid tumors are rare, noncancerous, locally aggressive tumors
- First and only FDA-approved targeted therapy developed specifically for adult patients with progressing desmoid tumors requiring systemic therapy

"With Nirogacestat, we are seeing more effective options for these patients."

Sean Warsch, MD

[•] SpringWorks Therapeutics, Inc. OGSIVEO (nirogacestat) US Prescribing Information. Published April 4, 2024. https://springworkstx.com/wp-content/uploads/2024/04/OGSIVEO-US-Prescribing-Information-04.04.24.pdf. Accessed October 7, 2025.

[•] Alman B, Attia S, Baumgarten C, et al. The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients. European Journal of Cancer. 2020. 127: 96-107.

Ogsiveo Overview: Packaging & Patient Education



Packaging:

Unique blister design supports adherence and dosing accuracy

Patient Counseling Focus:

- Dosing schedule and missed doses
- Adverse event discussions
- Adherence tracking

ADVANCED PRACTICE PROVIDER

- Assists in toxicity assessments
- Performs detailed system reviews and symptom checks
- Helps bridge communication between physicians and team
- "APPs are great at digging into symptoms during system reviews. That detailed communication really supports patient care."
- Elizabeth Dennis, MSN, APRN, FNP-C

MIP MULTIDISCIPLINARY CARE



NURSE

- Monitors labs and patient charts
- Flags side effects and collaborates with pharmacist
- Provides emotional and logistical patient support
- Guides symptom management and education
- "Nurses smooth the transition between treatment and appointments so patients can focus on healing."
- Paulina Barbera, RN

PHARMACIST

 Reviews drug interactions and performs medication reconcili-

ation

- Educates patients and caregivers
- Communicates dose adjustments and monitors side effects
- Supports adherence and access
- "I counsel patients and caregivers, addressing questions and supporting them throughout their treatment."
- Christina Koufos, PhormD, AAHIVP, CSP



PHARMACY TECHNICIAN

- Dispenses and processes medications
 Flags missing docu-
- mentation or steps in workflow
- Supports prior authorizations and access
- Communicates issues to the pharmacist
- "Techs are often the first to notice a missing step in the process and need confidence to speak up to the care team."
- Lindsey Scott





Financial Navigation:

- Benefits investigation & co-pay support
- Coordination with manufacturer programs and assistance foundations

NCODA Resources

PQI

PQI in Action

Treatment Support Kit


Patient Education Sheet

Treatment Discussion Guide

Epkinly® (Epcoritamab-bysp) in Action



- A subcutaneous bispecific antibody that targets CD20 on B-cells and CD3 on T-cells activating T-cell-mediated destruction of malignant B-cells
- FDA Accelerated Approval:
 - R/R DLBCL, not otherwise specified, including DLBCL arising from indolent lymphoma, and highgrade B-cell lymphoma after ≥ 2 lines of systemic therapy
 - o R/R FL after ≥ 2 lines of systemic therapy







Why It Matters:

 Expanding access to advanced immunotherapy in community settings

Program Infrastructure:

- EMR alerts & standardized orders
- CRS/ICANS protocols & emergency readiness
- Tocilizumab and supportive meds on hand

Team Collaboration:

- Align on start criteria and monitoring
- Weekly case reviews for appropriateness





Continuous Education:

- Staff training on bispecific mechanisms & AE management
- Patient teaching on safety and follow-up expectations

PQI

PQI in Action

Patient Education Sheet

Immunotherapy Hub

Closing Thoughts



What advice would you give to other practices looking to implement these therapies using NCODA resources?



QUESTION & ANSWER

NCODA PQI in Actions: Practical Strategies to Transform Oncology Care

Rebecca Bahr, PharmD, MBA

American Oncology Network

Paulina Barbero, BSN, RN
Northwell Health

Nick Bouchard, PharmD HOACNY